The Muscle Spasticity Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The historical growth trend in the Muscle Spasticity market indicates a strong growth over the years. The market size stood at $4.19 billion in 2024 and is projected to increase to $4.57 billion in 2025. The compound annual growth rate (CAGR) during this period is 9.1%.
By 2029, the Muscle Spasticity market is projected to reach a size of $6.41 billion, growing at a compound annual growth rate (CAGR) of 8.8%.
Download Your Free Sample of the 2025 Muscle Spasticity Market Report and Uncover Key Trends Now!The drivers in the muscle spasticity market are:
• Surge in investments in research and development
• Expansion of clinical indications
• Beneficial regulatory approvals and reimbursement policies
• Increasing prevalence of multiple sclerosis and emphasis on multimodal approach
The muscle spasticity market covered in this report is segmented –
1) By Drug Type: Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Other Drugs
2) By Route Of Administration: Oral, Intramuscular, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The trends in the muscle spasticity market are:
• The adoption of value-based reimbursement models in the muscle spasticity market is a significant trend.
• Integration of artificial intelligence and machine learning technologies are transforming the future of the muscle spasticity market.
• The market is experiencing a emerging trend is the adoption of telehealth and remote monitoring technologies.
• There is a growing focus on neurostimulation techniques and regenerative medicine approaches in the treatment of muscle spasticity.
The major players in the muscle spasticity market are:
• F. Hoffmann-La Roche Ltd.
North America was the largest region in the muscle spasticity market in 2023